glp 1 agonist risks GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Agonists For Obesity In

The propensity score was estimated using logistic regression as the probability of starting a GLP1 receptor agonist versus a DPP4 inhibitor conditional on a number of variables, including sociodemographic characteristics, medical history, other diabetes treatment, and markers of healthcare use, at cohort entry and stratified by country (etable 3)

retail pharmacies and telehealth providers

Arguably, the most clinically relevant basis for the potential of GLP-1 RAs in HF could be their effect on multiple cardiometabolic parameters that play intertwined roles across the HF-related diseases such as diabetes and obesity, which often co-exist

We did not include a study by Anazco et al because it did not compare GLP-1RA users to nonusers

You can also contact your Blue Cross and Blue Shield of Kansas representative.